ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.2 SEK | -4.64% | -5.26% | +44.00% |
05-02 | ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024 | CI |
02-22 | ODI Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+44.00% | 10.23M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.87% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- ODI Stock
- News ODI Pharma AB
- ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024